PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 509-518

  Riggio, Marina ^a   Polo, María Laura ^a   Blaustein, Matías ^b,c   Colman lerner, Alejandro ^b,c   Lüthy, Isabel ^a   Lanari, Claudia ^a   Novaro, Virginia ^a  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 8; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FOCAL ADHESION KINASE; LAMININ 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MYRISTYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR DIFFERENTIATION;

EID: 84857948950     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr303     Document Type: Article

References (47)

1. Feng,J. et al. (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem., 279, 41189-41196.
2. Sarbassov,D.D. et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
3. Carracedo,A. et al. (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene, 27, 5527-5541.
4. Wickenden,J.A. et al. (2010) Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Breast Cancer Res., 12, 202.
5. Perez-Tenorio,G. et al. (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer, 86, 540-545.
6. Wu,Y. et al. (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res., 10, R3.
7. Tokunaga,E. et al. (2006) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur. J. Cancer, 42, 629-635.
8. Beeram,M. et al. (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol., 18, 1323-1328.
9. Knuefermann,C. et al. (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene, 22, 3205-3212.
10. Stal,O. et al. (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res., 5, R37-R44.
11. Di Cosimo,S. et al. (2008) Targeted therapies in breast cancer: where are we now? Eur. J. Cancer, 44, 2781-2790.
12. Alvarez,R.H. et al. (2010) Emerging targeted therapies for breast cancer. J. Clin. Oncol., 28, 3366-3379.
13. Tokunaga,E. et al. (2007) Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res. Treat., 101, 249-257.
14. Mills,G.B. et al. (2001) The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin. Oncol., 28, 125-141.
15. Dillon,R.L. et al. (2010) Distinct biological roles for the akt family in mammary tumor progression. Cancer Res., 70, 4260-4264.
16. Lanari,C. et al. (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr. Relat. Cancer, 16, 333-350.
17. Polo,M.L. et al. (2010) Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One, 5, e10786.
18. Vazquez,S.M. et al. (2004) Three novel hormone-responsive cell lines derived from primary human breast carcinomas: functional characterization. J. Cell. Physiol., 199, 460-469.
19. Bruzzone,A. et al. (2009) Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J. Cell. Physiol., 219, 477-484.
20. Institute of Laboratory Animal Resources, C.o.L.S.N.R.C. (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
21. Lanari,C. et al. (2001) Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res., 61, 293-302.
22. Lee,G.Y. et al. (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods, 4, 359-365.
23. Dontu,G. et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev., 17, 1253-1270.
24. Kohn,A.D. et al. (1996) Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J. Biol. Chem., 271, 21920-21926.
25. Tamura,M. et al. (1998) Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280, 1614-1617.
26. Soneoka,Y. et al. (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res., 23, 628-633.
27. Kordon,E. et al. (1990) Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res. Treat., 17, 33-43.
28. Giulianelli,S. et al. (2008) Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis. Int. J. Cancer, 123, 2518-2531.
29. Soldati,R. et al. (2009) Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta? Breast Cancer Res. Treat., 123, 709-724.
30. Li,G. et al. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development, 129, 4159-4170.
31. Irie,H.Y. et al. (2005) Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol., 171, 1023-1034.
32. Maroulakou,I.G. et al. (2008) Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J. Cell. Physiol., 217, 468-477.
33. Li,X. et al. (2001) Akt/PKB regulates laminin and collagen IV isotypes of the basement membrane. Proc. Natl Acad. Sci. USA, 98, 14416-14421.
34. Vandermoere,F. et al. (2007) Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol. Cell. Proteomics, 6, 114-124.
35. Fortier,A.M. et al. (2010) Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells. FEBS Lett., 584, 984-988.
36. Sartorius,C.A. et al. (2005) Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res., 65, 9779-9788.
37. Wang,S. et al. (2011) Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis. Am. J. Physiol. Cell Physiol., 300, C657-C670.
38. Julien,S. et al. (2007) Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene, 26, 7445-7456.
39. Blanco-Aparicio,C. et al. (2007) Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis, 28, 584-594.
40. Hutchinson,J.N. et al. (2004) Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res., 64, 3171-3178.
41. Korkaya,H. et al. (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol., 7, e1000121.
42. Campbell,R.A. et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem., 276, 9817-9824.
43. Sun,M. et al. (2001) Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res., 61, 5985-5991.
44. Massarweh,S. et al. (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res., 68, 826-833.
45. Vicent,G.P. et al. (2006) Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways. Ann. N. Y. Acad. Sci., 1089, 59-72.
46. Miller,T.W. et al. (2009) Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res., 69, 4192-4201.
47. Miller,T.W. et al. (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest., 120, 2406-2413.